T

Teyi Pharmaceutical Group Co Ltd
SZSE:002728

Watchlist Manager
Teyi Pharmaceutical Group Co Ltd
SZSE:002728
Watchlist
Price: 8.73 CNY -3.43% Market Closed
Market Cap: 4.5B CNY
Have any thoughts about
Teyi Pharmaceutical Group Co Ltd?
Write Note

Teyi Pharmaceutical Group Co Ltd
Other Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Teyi Pharmaceutical Group Co Ltd
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
T
Teyi Pharmaceutical Group Co Ltd
SZSE:002728
Other Equity
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Other Equity
ÂĄ136.9m
CAGR 3-Years
N/A
CAGR 5-Years
14%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Other Equity
ÂĄ2.3m
CAGR 3-Years
-78%
CAGR 5-Years
-59%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Other Equity
ÂĄ18.5m
CAGR 3-Years
N/A
CAGR 5-Years
44%
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Other Equity
-ÂĄ36.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Other Equity
ÂĄ1.4m
CAGR 3-Years
-23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Teyi Pharmaceutical Group Co Ltd
Glance View

Market Cap
4.5B CNY
Industry
Pharmaceuticals

Teyi Pharmaceutical Group Co., Ltd. engages in the pharmaceutical manufacturing and pharmaceutical health industry. The company is headquartered in Jiangmen, Guangdong and currently employs 1,200 full-time employees. The company went IPO on 2014-07-31. The firm primarily provides Chinese traditional patent medicines, including cough arresting and phlegm removing medicine series, kidney reinforcing medicine series and anti-infection medicine series, among others. The firm's products mainly include tablets, granules, medicinal tea, syrup, decocted extracts, capsules, powder, ointment, cream, as well as oral solutions, among others.

Intrinsic Value
12.84 CNY
Undervaluation 32%
Intrinsic Value
Price
T

See Also

Back to Top